SCHEMBL348213

SCHEMBL348213

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(NC(=O)c3ccc(Cl)cc3)cc2C(S)c2nnc(C)s2)c1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.44
TP53 P04637 1/20 0.44
PTGDR2 Q9Y5Y4 4/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
STAT3 P40763 1/20 0.40
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
POLB P06746 2/20 0.38
NPC1 O15118 1/20 0.38
PTGS2 P35354 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL349217 0.89 PTGDR2 (0.49) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL349880 0.82 LMNA (0.39) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL348214 0.82 ALDH1A1 (0.51) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL13521963 0.81 PTGDR2 (0.48) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL347220 0.80 LMNA (0.40) LMNASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL350502 0.77 PTGDR2 (0.46) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL349218 0.76 CYP3A4 (0.46) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL350154 0.76 PTGDR2 (0.49) LMNAPTGDR2SMN1; SMN2MAPTRAB9A
SCHEMBL1943002 0.76 PTGDR2 (0.45) LMNATP53PTGDR2SMN1; SMN2MAPT
SCHEMBL348830 0.76 CYP3A4 (0.60) LMNATP53PTGDR2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247602-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-21 US disclosed
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2012-01-19 US disclosed
US-8071807-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2011-12-06 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-06-16 US disclosed
EP-2307362-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2010003120-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885TP53 4519/4885PTGDR2 2/4885
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885TP53 4519/4885PTGDR2 2/4885
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2277/4885TP53 4519/4885PTGDR2 2/4885
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2161/4885TP53 4540/4885PTGDR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.